Your liver does more than you think.
Yet 1 in 3 adults worldwide lives with MASLD, often silently.
The good news? Small, solid habits make a big difference.
Solid Habits, Strong Liver.

#WorldLiverDay

Liver fibrosis is common, silent, and often missed.

📊 >30,000 adults screened across Europe.
⚠️ 1.6% had confirmed chronic liver disease with fibrosis.
🍔Metabolic risk + 🍻alcohol =key drivers.

Early detection matters!

Published in The Lancet: authors.elsevier.com/c/1mvfPV-4XW...

Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD Fibrosis-4 Index (FIB-4) is a noninvasive tool for assessing liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD). Howev…

#FIB-4 is widely used for #fibrosis assessment. But what about its changes over time?📈

🌏 A large international study shows how dynamic #FIB-4 may predict fibrosis progression and clinical outcomes in #MASLD
💡 Interesting implications for clinical practice!

📖: www.sciencedirect.com/science/arti...

Honoured to receive the 🏅 Best Poster Presentation award 🏅at the #EASL #SLDSummit 2026 in Budapest 🇭🇺
A great opportunity to present and discuss data on platelet behaviour in #MASLD within an international scientific setting. Many thanks to all collaborators! 🙌

Presented data from my study at the #EASL #SLDSummit 2026 in Budapest 🇭🇺
I shared insights on #platelet activation and function 🧪 across different stages of #MASLD

A valuable opportunity for discussion and scientific exchange ✨️

📢 I’ve got wonderful news to share! 🏆 My abstract was accepted for @EASLnews #SLDSummit 2026! I’m looking forward to sharing my research 🧪🔬🩺in Budapest 🇭🇺 from 26-28 February. Register to join me there➡️https://easl.eu/sld2026

In 1203 🇮🇹 outpatients with #T2DM, #MASLD was present in 71% and significant fibrosis in 21%.

The EASL-EASD-EASO two-tier algorithm (#FIB4 → #FibroScan) showed high NPV but modest sensitivity, especially in patients with ↑BMI or ↑ALT ⚠️

🔗 dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/...

In #MASLD, not all Non-Invasive Tests perform the same worldwide! 🌍

In 17,792 pts (41 Countries), Agile3+ & Agile4 were the most accurate for advanced fibrosis and cirrhosis ✅️

The accuracy of common NITs like #FIB4, #ELF, #LSM varies by region ⚠️

🔗 Read more here: journals.lww.com/hep/abstract...

Weight gain >5% in MASLD? Liver risk almost doubles!

This study considered a global cohort of >10,000 MASLD patients 🌍

Reversing obesity brings risk back close to non-obese levels: dynamic weight matters ✅️

#MASLD #Obesity #MetabolicHealth #Fibroscan

journals.lww.com/hep/abstract...

Effect of Hypertension on Long-term Adverse Clinical Outcomes and Liver Fibrosis Progression in MASLD Hypertension is common in metabolic dysfunction-associated steatotic liver disease (MASLD), but its impact on long-term clinical outcomes and disease progression remains unclear. This study investigat...

Hypertension = hidden accelerator of MASLD
📚 An international, multicentre study shows that hypertension 📈 increases the risk of adverse clinical outcomes 🩺 and accelerates fibrosis progression in MASLD.
Read it here: www.journal-of-hepatology.eu/article/S016...

#MASLD #hypertension #LiverResearch

Platelet Functional Profile Is Altered in Metabolic Dysfunction‐Associated Steatotic Liver Disease Background and Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease, often progressing to fibrosis and up to cirrhosis. Platelet activati...

🧪 Platelets tell the story of MASLD progression:
- Early stages→ hyperactive
- Advanced fibrosis→ reduced reactivity despite high activation

🔬 Proud to be joint first author of this Liver International study

📄 Open access: onlinelibrary.wiley.com/doi/10.1111/...

#MASLD #Hepatology #Platelets

Liver Fibrosis Testing in Patients With Type 2 Diabetes: The Time Is Now In a study in this issue of Diabetes Care, Caussy et al. (1) have looked at the outcomes of noninvasive fibrosis testing in patients with type 2 diabetes a

Liver fibrosis in Type 2 diabetes: a silent threat

📊 >17% of T2DM patients are at intermediate/high risk of advanced fibrosis

🧪 Time to make non-invasive testing routine

📄 New editorial in #DiabetesCare

#MASLD #T2DM #LiverHealth #Fibrosis

Read it here: doi.org/10.2337/dci2...

All together at the Home of Hepatology in Amsterdam 🇳🇱 for #EASLcongress - and guess who's with us? It's Livy, the #EASL mascot! Great science, great people, great vibes 🔬💫✨️

#EASL2025 #Hepatology #ScienceNetworking

Back at #EASLcongress today with another poster! Today's topic: why a #multidisciplinary approach matters in MASLD management

Collaboration makes a difference - in research and in care. Happy to chat if you're around or curious!

#EASL2025 #MASLD #MultidisciplinaryClinic #LiverHealth #PosterSession

Glad to be presenting two posters today at #EASLcongress - and another
one tomorrow!
📊 We're exploring MASLD and the role of non-invasive tests! 🩺

Feel free to stop by or get in touch if you'd like to know more!

#MASLD #NITs #Hepatology #LiverResearch #PosterSession #EASL2025

Staging liver fibrosis and cirrhosis using non-invasive tests in people with chronic hepatitis B to inform WHO 2024 guidelines: a systematic review and meta-analysis Non-invasive tests (aspartate aminotransferase-to-platelet ratio index [APRI] and transient elastography [FibroScan]) were recommended in the 2015 WHO…

🩺Hepatitis B care has changed📊 New WHO fibrosis cutoffs mean earlier treatment, less liver biopsy, better outcomes.

Check out our new study here: www.sciencedirect.com/science/arti...

#WHO #LiverHealth #ChronicHepatitisB #NonInvasiveTests #LiverFibrosis

EASL SLD Summit 2025 The EASL SLD Summit 2025 offers a comprehensive exploration of steatotic liver disease, over three days. The programme integrates practical clinical education w

🚀Excited to share my groundbreaking research for #EASL #SLDSummit 2025 in Estoril 🇵🇹 from 23-25 January 🔬 Join me in advancing the fight against steatotic liver disease. Let's make a difference together! 🌟Register for the summit now: ctt.ec/wqm_y+

Could liver stiffness predict HCC before clinical signs appear? 🔬🔍✨

Our latest editorial explores how transient elastography could foresee liver cancer risk in chronic hepatitis B patients

👉 DOI 10.3350/cmh.2024.0817

Full article: www.e-cmh.org/journal/view...

What a fantastic Masterclass hosted by #EASL and #AASLD in #Savannah.
An unforgettable event and an exceptional opportunity to #connect with global experts, and exchange ideas in #Liver research. A truly enriching and inspiring experience!